NEWS & EVENTS2021-01-19T18:23:08+00:00


Please check back here often for updates and news related to the Company’s development and the advancement of its compounds.

Please check the Articles section for related materials and background information on the development of opioid analgesics and opiate addiction treatments.

Phoenix PharmaLabs Announces new Offering with Netcapital

January 19th, 2021|

Full Article

Phoenix PharmaLabs Strengthens its Position as a Developer of Next Generation Pain Pharmaceuticals with Acquisition of a Portfolio of NOP/Mu Agonist Compounds

January 8th, 2021|

Full Article

Dr. Lawrence Toll Presents at NCATS-Sponsored Symposium

February 9th, 2019|

Phoenix PharmaLabs is very pleased to announce that our chief neuropharmacologist and co-founder, Dr. Lawrence Toll, will present a poster entitled: “In Vitro and In Vivo Profile of PPL-103: A Mixed Opioid Partial Agonist Analgesic or Drug Abuse Medication”, at the upcoming National Center for Advancing Translational Sciences (NCATS)-sponsored symposium The Opioid Crisis and the Future of Addiction and Pain Therapeutics: Opportunities, Tools and Technologies.

This symposium, which will take place February 7-8 at the Natcher Auditorium on the NIH Campus in Bethesda, MD., will feature an All-Star line-up of addiction and pain researchers. NCATS, one of 27 Institutes and Centers at the National Institute of Health (NIH), was established to transform the translational process so that new treatments and cures for disease can be delivered to patients faster. This symposium is connected with the HEAL Initiative. HEAL (Helping to End Addiction Long-Term(sm)) Initiative is a trans-agency effort to speed scientific solutions to stem the national opioid public health crisis.

Dr. Toll’s poster will describe the unique profile of PPL-103 as a non-addictive opioid that could be a superior analgesic with greatly reduced addition liability and fewer side-effects compared to traditional opiates, as well as the drug’s potential as a treatment for addiction.

The full schedule can be found here.

Lilly Joins the Push for Non-Opioid Painkillers

October 26th, 2018|

In Pharma

Lilly joins the push for non-opioid painkillers

 By Maggie Lynch

Eli Lilly acquires exclusive worldwide rights for non-opioid treatment for chronic pain from Centrexion through a licensing agreement.


Pain Medicine is Evolving – A Non-Addictive Opioid?

September 28th, 2018|

A non-addictive opioid under development by Phoenix PharmaLabs (Utah), PPL-103, has demonstrated the potential to be a treatment for opioid, as well as cocaine, addictions, as published in a poster by Lawrence Toll, PhD, professor of biomedical science at the Charles E. Schmidt College of Medicine at Florida Atlantic University, and chief neuropharmacologist of Phoenix PharmaLabs.  He presented the results at a February 2018 National Center for Advancing Translational Sciences-sponsored symposium.  PPL-103 demonstrated an ability to reduce cocaine self-administration among rats, particularly those who were dependent on cocaine, completely blocking reinstatement of cocaine-seeking.  The drug showed reduced addiction liability and fewer side effects compared to traditional opioids and may have potential as a treatment for drug abuse.  PPL-103 is a patented analog that binds strongly to all three opioid receptors in the brain, partially stimulating the receptors in a more balanced manner.  This partial stimulation derives potent analgesic benefit, but is not strong enough to produce serious side effects associated with any single receptor, resulting in an opioid analgesic that appears to be non-addicting.

Load More Posts
Go to Top